Abstract: By using a semi-quantitative immunoblotting technique, we have analyzed serum immunoglobulin G (IgG) reactivities of patients with limited cutaneous systemic sclerosis and anticentromere antibodies, patients with diffuse systemic sclerosis and antitopoisomerase 1 antibodies, patients with diffuse systemic sclerosis without antitopoisomerase 1 or anticentromere antibodies and age-and gender-matched healthy controls with normal human skin fi broblasts and HEp-2 cells antigens. Serum IgG reactivities of patients with diffuse systemic sclerosis and antitopoisomerase 1 antibodies differed signifi cantly from those of healthy controls or systemic sclerosis patients in other groups for reactivity with fi broblast proteins. IgG from patients with antitopoisomerase 1 antibodies bound to a 90 kDa fi broblast band and to a 100 kDa protein band in a HEp-2 cell protein extract. These two bands were further identifi ed as DNA topoisomerase 1. Our results indicate that IgG from patients with diffuse systemic sclerosis bind DNA topoisomerase 1 in normal human fi broblasts extracts.
O R I G I N A L R E S E A R C H
IgG from patients with systemic sclerosis bind to DNA antitopoisomerase 1 in normal human fi broblasts extracts 
Introduction
Systemic sclerosis (SSc) is a connective tissue disease characterized by vascular hyperreactivity, obliterative microvascular phenomena and by skin and internal organs fi brosis. Endothelial cells, fi broblasts and leukocytes, particularly monocytes and lymphocytes participate in the pathogenesis of the disease, although none of these cells has been identifi ed as the unique initiating factor (Tamby et al 2003; Servettaz et al 2006) .
Several lines of evidence suggest that unchecked activation of fi broblasts is involved in SSc. Thus, fi broblasts from SSc patients are activated to produce high amounts of extracellular matrix proteins such as types I and III collagens, proteoglycans, fi bronectin, and metalloproteinase inhibitors (Leask et al 2002) . This might result from constitutive dysregulations of transforming growth factor beta (TGFβ) signaling pathway or from the infl uence of environmental factors, ie, excess of cytokines synthesis or targeting by autoantibodies.
Many autoantibodies have been detected in the serum of SSc patients, including disease specifi c such as anticentromere antibodies, associated with limited cutaneous SSc (Moroi et al 1980; Steen et al 1988) ; antitopoisomerase 1 antibodies associated with diffuse SSc (Steen et al 1988; Weiner et al 1988) ; and anti-RNA-polymerase III antibodies which are associated with renal involvement (Bunn et al 1998) . In addition, non specifi c autoantibodies have also been identifi ed in the serum of SSc patients, including antifi brillin 1 (Tan et al 1999) , antiendothelial cell antibodies (AECA) (Ihn et al 2000; Sgonc et al 2000; Garcia de la Pena-Lefebvre et al 2004) , and antifi broblast antibodies (AFA) (Brentnall et al 1982; Alderuccio et al 1989;  Tamby et al Chizzolini et al 2002; Ronda et al 2002; Zhou et al 2005; Baroni et al 2006) . Antifi broblast antibodies can activate fi broblasts and induce extracellular matrix proteins synthesis (Chizzolini et al 2002) . DNA topoisomerase 1 was recently identifi ed as a target of AFA (Henault et al 2004) . However, further experiments provided evidence that these antibodies did not target directly topoisomerase 1 expressed at the fi broblast surface but rather recognized membrane-bound topoisomerase 1 (Henault et al 2004) . Other target antigens of antifi broblast antibodies have been identifi ed: namely fi brillin-1 (Zhou et al 2005) and platelet-derived growth factor (PDGF) receptor (Baroni et al 2006) .
In order to confi rm these results and/or to identify specifi c target antigens of AFA in SSc patients, we decided to analyze reactivity patterns of immunoglobulin G (IgG) and IgM from SSc patients and age-gender-, and parity-matched healthy controls with fi broblasts.
Materials and methods Patients
All patients gave their written informed consent. Limited cutaneous SSc was defi ned by skin thickening in areas solely distal to the elbows and knees, with or without facial involvement; diffuse SSc was defi ned by the presence of skin thickening proximal, as well as distal, to the elbows and knees, with or without facial or truncal involvement (LeRoy et al 1988) . Sixty patients were included in the study: 20 (16 females and 4 males, mean age 53.5 ± 15.2 years) with diffuse SSc and antitopoisomerase 1 antibodies, 20 (all females, 56.7 ± 12.8 years) with limited cutaneous SSc and anticentromere antibodies and 20 (14 females and 6 males, mean age 50.9 ± 10.9 years) with diffuse SSc and no antitopoisomerase 1 or anticentromere antibody. For these 3 groups, disease durations were measured from the onset of fi rst non-Raynaud's phenomenon symptom (11.3 ± 9.6 years, 9.4 ± 9.5 years, 5.6 ± 5.4 years in the 3 groups, respectively). Interstitial lung disease, assessed by chest high-resolution computed tomodensitometry and abnormal pulmonary function test values (total lung capacity or vital capacity less than 80% of predicted values and/or diffusing capacity Ͻ75% of that predicted) was present in all patients with antitopoisomerase 1 antibodies, in 13 patients without antitopoisomerase 1 or anticentromere antibody and none of the patients with anticentromere antibodies. Pulmonary arterial hypertension, defi ned as systolic pulmonary artery pressure was Ͼ40 mm Hg (Mukerjee et al 2003) as measured by Doppler echocardiography, was diagnosed in 4 patients with antitopoisomerase 1 antibodies, 2 patients with anticentromere antibodies and 3 patients without antitopoisomerase 1 or anticentromere antibody. None of the patients included had cancer or another connective tissue disease. None of the patients received corticosteroids or immunosuppressive therapy. Sixty unrelated healthy age-, gender-and parity-matched donors served as controls.
Ig sources
Serum samples were obtained from patients and controls and stored in aliquots at -80 °C until tested. Mean serum IgG and IgM concentrations determined by nephelometry were respectively: 10.6 ± 2.9 and 1.4 ± 0.8 mg/ml in patients with anticentromere antibodies, 13.9 ± 3.9, 1.7 ± 0.74 mg/ml in patients with antitopoisomerase 1 antibodies, 14.4 ± 3.3 and 1.9 ± 1.0 mg/ml in patients without specifi c autoantibody and 12.0 ± 2.8 and 1.6 ± 0.7 in healthy controls. Serum IgG and IgM concentrations did not differ signifi cantly between patients in the different groups and controls. A therapeutic preparation of normal human IgG, intravenous immunoglobulin (IVIg) and normal human polyclonal IgM (LFB, Les Ulis, France) served as internal standards.
Cell culture Fibroblasts
Normal human dermal fi broblasts were cultured from histologically normal skin obtained in 3 donors undergoing resection of basocellular carcinoma. Biopsy specimen were cut into small sections and seeded into Petri dishes and then into 162 cm 2 plastic fl asks. Fibroblasts were grown in Dulbecco's modifi ed Eagle's medium (DMEM) with 10% heat-inactivated fetal calf serum, 2 mM L-glutamine, 10 mM Hepes, 100 U/ml penicillin, 100 μg/ml streptomycin (Life Technologies Ltd, Auckland, NZ) at 37 °C in 5% CO 2 . When confl uent, the cells were detached using 0.05% trypsin with 2 μM EDTA.
HEp-2 cells
HEp-2 cells were obtained from EuroBio (Les Ulis, France) and cultured at 37 °C in 5% CO 2 in 162 cm 2 fl asks in DMEM supplemented with 10% heat-inactivated fetal calf serum, 2 mM L-glutamine, 10 mM hepes, 20 mM sodium pyruvate, 100 U/ml penicillin, 100 μg/ml streptomycin (Life Technologies Ltd). When confl uent, the cells were detached using 0.05% trypsin, 2 μM EDTA.
Detection of antibody reactivities
For each patient and healthy control, antinuclear antibodies were investigated by indirect immunofl uorescence on HEp-2 cells and considered positive at a dilution Ն1/160. Anticentromere antibodies were characterized by a pattern of discrete dots in cells lined up on the metaphase plate in dividing interphase cells. Antitopoisomerase 1 antibodies were detected by ELISA with a commercial kit (Inova Diagnostics Inc, San Diego, CA, USA) using purifi ed calf thymus topoisomerase 1 and sera diluted 1:100.
IgG and IgM reactivities were analyzed using a semiquantitative immunoblotting technique with normal human dermal fibroblasts and HEp-2 cells. Cellular protein extracts were performed in a buffer containing 4% sodium dodecyl sulfate, 1.45 M 2-mercaptoethanol, 125 mM Tris/HCl pH 6.8, 1 μg/ml aprotinin, 1 μg/ml pepstatin and 1 μg/ml leupeptin and then sonicated 4 × 30 s Garcia de la Pena-Lefebvre et al 2004) . Equal amounts of solubilized proteins were subjected to preparative sodium dodecyl sulfate-polyacrylamide gel electrophoresis through 10% polyacrylamide gels. The proteins were then transferred onto nitrocellulose membranes for 1 h at 0.8 mA/cm 2 using a semi-dry electroblotter model A (Ancos, Hojby, Denmark). After blocking with phosphate buffer saline -0.2% Tween ® for 90 min, the membranes were incubated with sera for 4 h at room temperature at 200 μg/mL for IgG and 20 μg/mL for IgM in a cassette miniblot system (Immunetics Inc., Cambridge, MA, USA). They were then extensively washed before being incubated with secondary rabbit antihuman Fc-γ of antihuman Fc-μ antibody coupled to alkaline phosphatase (Dakocytomation, Golstrup, Denmark) for 90 min at room temperature. Immunoreactivities were revealed using the nitroblue tetrazolium-5-bromo-4-chloro-3-indolyl-phosphate substrate (Sigma, St. Louis, MO, USA) (Garcia de la Pena- Lefebvre et al 2004; Tamby et al 2005) . Immunoreactivities were quantifi ed by scanning the membranes with a densitometer (Epson Perfection 1200S, Seiko Epson Corporation, Nagano-Ken, Japan). The membranes were then stained with colloidal gold (Protogold; ® Biocell, Cardiff, UK) and subjected to a second densitometric analysis to quantify transferred proteins. This approach allows the immunoreactivity repertoires to be compared by referring to their respective protein peaks corrected for electrophoretic migration defects by superimposing corresponding protein peaks by means of computer analysis. Standard IgM or IgG preparations included in each blot, allow the rescaling of the membranes transferred with a given protein extract and to adjust for the intensity of labelling on different membranes Garcia de la Pena-Lefebvre et al 2004) . All experiments were performed twice.
Rabbit polyclonal antibody raised against amino acids 685-765 of human DNA topoisomerase 1 recombinant protein (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was tested in immunoblots during 90 min at room temperature at dilutions of 1:500, and 1:1000 for reactivity with fi broblasts proteins extracts. Immunoreactivities were assayed using an alkaline phosphatase conjugated goat antirabbit IgG antibody (Santa Cruz) and revealed using nitroblue tetrazolium-5-bromo-4-chloro-3-indolyl-phosphate) (Sigma).
Protein sequencing
To identify the target antigens, we performed an additional SDS-PAGE protein electrophoresis with a fi broblast extract in 10% polyacrylamide gels and dissected bands of interest. We then performed a passive adsorption onto a polyvinyle difl uoride (PVDF) membrane (Messer et al 1997) and not an electrotransfer, in order to favor the protein binding onto the membrane in a nondestructive manner for subsequent analysis of the separated proteins of interest. The proteins were derivatized and sequenced by automated Edman's degradation using a PE Applied Biosystems 492 cLC protein sequencer (Perkin Elmer, Wellesley, MA, USA) allowing the identifi cation and quantifi cation in the range of femtomoles of the amino acids released.
Statistical analyses
Because of the large number of reactivities identifi ed in the blots, we decided to submit the data to multivariate statistical analysis. Therefore we used IGOR software (Igor Pro 3.16, Wavemetrics Inc, Lake Oswego, OR, USA) with specially designed software packages (Nobrega et al 1993) , and Statview software (Statview 5.0; SAS institute Inc., Cary, NC, USA). Densitometry curves of IgG and IgM reactivities of each patient and control on each of the different protein extracts were divided into sections surrounding individual peaks of immunoreactivity on each substrate. In order to discriminate between groups of individuals, the peak amplitudes corresponding to these sections were submitted to principal component analysis (Nobrega et al 1993; Mouthon et al 1996) . Principal component analysis data were then subjected to linear discriminant analysis, and the individual linear discriminant analysis factor 1 coordinates of each patient or healthy control in the 2 groups were compared using a paired Wilcoxon test. Repertoires of reactivities of patients in each group were compared two by two by using the same procedure, except that the individual linear discriminant analysis factor 1 coordinates of each patient in the 2 groups were compared using a Mann-Whitney test.
Results

IgG and IgM reactivities of patients and healthy controls with fi broblast antigens
IgG and IgM reactivity patterns with fi broblast antigens were homogeneous in terms of protein bands recognized and intensity of reactivities among healthy individuals and patients in each group. As depicted in Figure 1 , IgG from healthy individuals bound to 5 to 8 protein bands in the fi broblast extract, with expression of three main immunoreactivities of approximately 53, 44, and 33 kDa, respectively ( Figure 1A) . Two other minor IgG reactivities were directed against low molecular weight proteins, and some patients expressed individual specifi c reactivities. IgG from patients in the different groups also bound to 6 to 10 protein bands in the fi broblast extract including immunoreactivities directed toward the same 53, 44, and 33 kDa bands. In addition to these bands, IgG from patients with limited cutaneous SSc and anticentromere antibodies ( Figure 1B ) bound with low intensity to a 80 kDa antigen. IgG from patients with diffuse SSc and antitopoisomerase 1 antibodies ( Figure 1C) expressed a high intensity reactivity with the 44 kDa protein band as compared with those expressed by IgG from patients in other groups and healthy controls. Interestingly, almost all patients with diffuse SSc and antitopoisomerase 1 antibodies bound to two 90 and 65 kDa protein bands, whereas IgG from patients with limited cutaneous SSc and anti anticentromere antibodies and healthy controls did not. Finally, IgG from several patients without specifi c autoantibody bound to the two 90 and/or 65 kDa fi broblasts protein bands, whereas other patients in this group did not ( Figure 1D) . IgG from several patients in each group expressed individual specifi c reactivities.
IgM from patients and healthy individuals bound to three to fi ve protein bands in the fi broblast extract and with a high intensity reactivity with the 53kDa protein band (data not shown). component analysis followed by linear discriminant analysis and non parametric tests, as previously described. IgG reactivities from patients with diffuse SSc and antitopoisomerase 1 antibodies with fi broblasts antigens different signifi cantly from those of healthy controls, whereas no signifi cant difference was observed between limited cutaneous SSc with anticentromere antibodies and their controls and diffuse SSc without antitopoisomerase 1 or anticentromere antibody and their controls (Table 1) .
Multiparametric analysis of IgG and
IgM reactivities from patients with limited cutaneous SSc with anticentromere antibodies were signifi cantly different from those of healthy controls, whereas no signifi cant difference was observed between patients in other groups and their respective healthy controls (Table 1) .
Multiparametric analysis of serum reactivities from patients compared two by two differed in the case of IgG from patients with diffuse SSc with antitopoisomerase 1 antibodies vs patients with diffuse SSc without antitopoisomerase 1 or anticentromere antibody and in the case of IgM from patients with diffuse SSc and antitopoisomerase 1 antibodies vs patients with limited cutaneous SSc with anticentromere antibodies (Table 2) .
IgG and IgM reactivities of patients and healthy controls with HEp-2 cells antigens
In order to better characterize the cell specifi city of AFA, we further performed experiments with HEp-2 cells, the reference source of nuclear antigens. IgG reactivity patterns were relatively homogeneous among healthy individuals and among patients in each group when tested toward HEp-2 cells protein extracts. IgG from patients with antitopoisomerase 1 antibodies recognized 3-6 protein bands in HEp-2 cells extract, including one major band of 100-kDa, whereas IgG from patients with anticentromere antibodies recognized 4-8 bands, including two major bands of 65 and 80 kDa, whereas none of them bound to the 100-kDa band (Figure 2) . IgG from patients without antitopoisomerase 1 or anticentromere antibody recognized 6-10 HEp-2 cells bands, including the 100-kDa protein band in 5/20. IgM reactivity patterns with HEp-2 cells protein extracts were relatively homogeneous among healthy individuals and among patients in each group. No difference was observed between IgM reactivities of patients in each group and healthy individuals (data not shown).
Multiparametric analysis of IgG and IgM reactivities of patients and healthy controls with HEp-2 cells antigens
Principal component analysis of the data discriminated between the IgG reactivity patterns of SSc patients in each group and healthy controls as well as between patients in the different groups compared two by two (Tables 1 and 2) . IgM reactivity patterns with HEp-2 cells protein extracts were relatively homogeneous among healthy individuals and among patients in each group. No signifi cant difference was observed between IgM reactivities of patients in each group and controls or between patients in each group tested two by two, with the exception of patients with antitopoisomerase 1 antibodies versus healthy individuals (Tables 1 and 2 ). We thus demonstrated that IgG reactivities from SSc patients in the different groups were not specifi c to fi broblasts antigens but also bound HEp-2 cells antigens.
Characterization of the 100-kDa target antigen in fi broblasts
We incubated the fi broblast protein extract with rabbit polyclonal antibodies raised against amino acids 685-765 of human DNA topoisomerase 1 recombinant protein as indicated in Materials and methods. This antibody bound to the same 90 kDa protein band that was recognized by serum IgG from patients with antitopoisomerase 1 antibodies (data not shown). We also tested the polyclonal goat antitopoisomerase 1 antibody on HEp-2 protein extract and observed that this Ab bound to the 100 kDa protein band (data not shown).
We further sequenced the 90-kDa protein band, as described in Materials and methods. DNA-topoisomerase I was identifi ed by sequencing the 10 to 25 N-terminal amino acids: SQIEADFRLNDSHKH of this protein.
Thus, the N-terminal sequence of the protein started at position 10, suggesting a lysis of the nine fi rst amino acids during preparation of the protein sample (data not shown). Thus, AFA from patients with diffuse SSc with or without antitopoisomerase 1 antibodies bind to fi broblast topoisomerase 1.
Discussion
It is now well established that SSc patients express antifibroblasts antibodies (Brentnall et al 1982; Alderuccio et al 1989; Chizzolini et al 2002; Ronda et al 2002; Henault et al 2004) . Chizzolini and colleagues (2002) reported that the prevalence of AFA was signifi cantly higher in diffuse SSc than in limited cutaneous SSc patients. Thus, our observation that limited cutaneous or diffuse SSc exhibit signifi cantly different reactivity patterns with fi broblasts antigens is not unexpected. Unfortunately, in their report, Chizzolini and colleagues do not mention the prevalence of antitopoisomerase 1 antibodies in SSc patients tested.
To our knowledge, very few studies investigated the specifi city of AFA in SSc patients. We here provide evidence that IgG from diffuse SSc patients with antitopoisomerase 1 antibodies express two main bands of reactivity of 65 and 90 kDa with fi broblasts antigens, whereas patients with limited cutaneous SSc and anticentromere antibodies and healthy controls do not. Our patients had IgG antitopoisomerase 1 antibodies, and we knew from the literature that antitopoisomerase 1 IgG reactivities may bind to a 70 kDa protein band corresponding to a degraded form of topoisomerase 1 in cellular extracts. Thus, we postulated that IgG immunoreactivities identifi ed in these patients might be directed to topoisomerase. This was confi rmed by N-terminal sequencing, since an amino acid sequence compatible with N-terminal sequence of DNA topoisomerase 1 was identifi ed in the 90 kDa band. Although we did not perform any experiment to identify the same target antigen in the 65 kDa band, we postulate that this band also contains DNA topoisomerase 1. Thus, it has now been well documented for near twenty years that patients with SSc bind to a 70 kDa antigen in Hela cells extracts and that the target antigen of the anti-Scl-70 Abs is a degraded form of topoisomerase 1 (Kumar et al 1988) , and it was postulated that reactivities directed towards Hela cells proteins of 63 to 77 kDa molecular weights bound to topoisomerase 1 (Briolay et al 1989) .
Importantly, our data confi rm the fi nding of Henault and colleagues (2004) who recently identified DNA topoisomerase 1 as the target of AFA, with evidence that antitopoisomerase 1 antibodies display antifi broblast activity by reacting with determinants at the fi broblast surface.
Although it has not been demonstrated yet, one may speculate that IgG antitopoisomerase 1 antibodies from patients with diffuse SSc might bind to their target antigen at the fi broblast surface and activate these cells. Indeed, in SSc patients, AFA have been shown to induce fi broblasts activation in vitro and a pro-adhesive and pro-infl ammatory phenotype of these cells (Chizzolini et al 2002) . Thus, IgG binding to the surface of fi broblasts could induce an autocrine production of cytokines such as interleukin (IL)-1α, IL-1β, and IL-6 which could up-regulate the adhesive molecule intercellular adhesion molecule-1 on fibroblast surface (Chizzolini et al 2002) .
Interestingly, we have previously analyzed IgG antibodies repertoires in SSc patients and shown that IgG reactivity with a 100-kDa tissue and endothelial cell antigen identifi ed as topoisomerase 1 distinguished between limited cutaneous and diffuse SSc patients (Garcia de la Pena-Lefebvre et al 2004), whereas two 75-and 85-KDa protein bands identifi ed as centromeric protein B were recognized by patients with limited cutaneous SSc (Servettaz et al 2006) .
Prominent recognition of a 90 kDa band in fi broblasts versus a 100 kDa band in endothelial cells (Garcia de la Pena-Lefebvre et al 2004) or HEp-2 cells might be the consequence of discrepancies in the amounts of proteases or free radicals in the different cell culture mediums between fi broblasts, HEp-2 cells, and endothelial cells.
In the present report, IgG from close to 50% of patients without antitopoisomerase 1 or anticentromere antibody bound to two 65 and/or 100 kDa fi broblasts protein bands, with prominent binding to the 65 kDa Hep-2 cell protein band. These data confi rm those obtained in previous work performed with endothelial cell antigens that IgG from 50% of patients without antitopoisomerase 1 or anticentromere antibody, as assessed by ELISA, bound to the 100-kDa endothelial cell antigen identifi ed as topoisomerase 1 (Garcia de la Pena-Lefebvre et al 2004) . Thus, IgG from SSc patients with antinuclear antibodies without documented antitopoisomerase 1 specifi city as assessed ELISA may bind to 90 kDa protein bands in fi broblasts extracts and/or 100 kDa antigens in endothelial cells and HEp-2 cell extracts. Thus, in previous work, we reported that antitopoisomerase 1 antibodies were detected in 9 (8.1%) patients who had no antitopoisomerase 1 antibody as determined by ELISA. Patients with antitopoisomerase 1 antibodies had an almost similar phenotype without distinction between ELISA or immunoblot approaches (Tamby et al 2007) .
Reactivities detected by immunoblotting refl ect the specifi c binding of the variable regions of IgM and IgG antibodies to tissue antigens (Mouthon et al 1995) . Since we used the same fi broblasts sources to test all patients, it could be argued that some of the scored reactivities could be specifi c to alloantigens. Moreover graft versus host disease reactions attributable to the persistence of allogeneic fetal cells in the skin of women for years after the pregnancy have been proposed to play a role in the development of SSc (Artlett et al 1998; Nelson et al 1998) . In this study, female SSc patients were matched with healthy women for parity, and in light of the absence of any difference between them, it is extremely unlikely that alloantigen recognition could explain the results obtained herein. Finally, the approach does not exclude that some of the epitopes identifi ed by IgG in immunoblots may differ from those expressed by native proteins. The technique allows, however, for the comparative analysis of repertoires of Igs from different individuals (Artlett et al 1998; Nelson et al 1998) .
We here provide evidence that IgG from patients with limited cutaneous or diffuse SSc exhibit signifi cantly different reactivity patterns with fi broblasts antigens, and confi rm that IgG from patients with diffuse SSc bind to topoisomerase 1 in fi broblasts extracts. The function of these antibodies needs to be investigated.
